Goldman Sachs: Now Is The Time To Get In On Teva's Turnaround

Teva Pharmaceutical Industries Ltd (ADR) TEVA announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs.

The Analyst

Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with a price target boosted from $15 to $20.

The Thesis

Teva's cost-cutting plan marks a turning corner event for the Israel-based company, Rubin said in a note. The company is now in the early stages of a "credible turnaround," which is being led by new CEO Kåre Schultz, who has a history of under-promising and over-delivering.

While there will still be investor skepticism, the company's game-plan also marks the first time it has delivered a "concrete strategy" towards deleveraging the company, the analyst said. Specifically, a 4 times  net leverage target for 2020 would likely be accompanied with EBITDA growth from $5.7 billion in 2018 to $6.5 billion in 2019, which would bring the company to its net leverage target.

Teva's stock will also benefit from the Street moving their numbers higher which marks a reversal of a bearish shift since the company's August 2016 acquisition of Actavis Generics.

Price Action

Shares of Teva gained 6 percent to trade around $18.32 Friday morning.

Related Links:

Analyst Eats 'Some Humble Pie,' Says Teva Needs To Deliver On Greater Visibility In Coming Months

A Look At Teva's Big Week

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorUpgradesPrice TargetTop StoriesAnalyst RatingsGeneric drugsGoldman SachsisraelJami RubinKare Schultzpharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!